What Causes Nosebleeds in HHT
Nosebleeds in HHT are caused by fragile telangiectasias (abnormal dilated blood vessels) in the nasal mucosa that bleed spontaneously or with minimal trauma, driven by underlying VEGF excess and dysregulated angiogenesis from mutations in genes like ENG or ACVRL1. 1
Underlying Pathophysiology
The root cause is genetic mutations that disrupt normal blood vessel development:
- Mutations in ENG (HHT type 1) or ACVRL1/ALK1 (HHT type 2) account for approximately 85% of cases 2
- These mutations lead to VEGF (vascular endothelial growth factor) excess 1
- The VEGF excess supports abnormal growth of telangiectasias—dilated, fragile blood vessels that lack normal capillary beds 1
- These telangiectasias form direct artery-to-vein connections without the structural integrity of normal vessels 2
Why the Nose Specifically
Nasal telangiectasias are the most common manifestation, occurring in over 90% of adults with HHT 1, 3:
- The nasal mucosa is particularly vulnerable due to constant exposure to airflow and environmental factors
- Drying and cracking of the fragile nasal mucosa triggers bleeding from these abnormal vessels 1
- The telangiectasias appear as large, prominent vascular lesions on endoscopy, particularly in the anterior and posterior nasal fossae 4
Severity Correlates with Lesion Characteristics
The morphology and distribution of nasal telangiectasias directly impacts bleeding severity 4:
- Large and prominent telangiectasias correlate with higher frequency of epistaxis
- Greater number of nasal subsites involved correlates with higher intensity of nosebleeds
- Posterior nasal lesions are particularly problematic
Clinical Impact
Epistaxis in HHT is not trivial bleeding:
- Can last hours per day 1
- Causes significant psychosocial morbidity, social isolation, and difficulties with employment and daily activities 1
- Leads to iron deficiency anemia in nearly half of affected individuals 3
- May require blood transfusions in severe cases 5
Important Clinical Caveat
While epistaxis is the hallmark symptom, approximately 3% of HHT patients may not develop recurrent epistaxis even by age 60-70, leading to delayed or missed diagnosis 6. These atypical presentations can result in serious complications like cerebral hemorrhage before HHT is recognized, so clinicians should maintain suspicion for HHT even without classic epistaxis when other features (telangiectasias, family history, visceral AVMs) are present.